AI Article Synopsis
- Allergic rhinitis (AR) is an IgE-mediated inflammatory disease, and intranasal phototherapy is proposed as a potentially effective treatment, although more rigorous research is needed.
- A pilot study will involve 40 AR patients, randomly assigned to either receive intranasal phototherapy or a placebo, assessing their nasal symptoms over two weeks.
- The results aim to support further large-scale trials to evaluate the safety and effectiveness of this noninvasive treatment for AR, especially for patients unresponsive to traditional therapies.
Article Abstract
Introduction: Allergic rhinitis (AR) is an immunoglobulin E (Ig E)-mediated inflammatory disease. Intranasal phototherapy is a promising treatment modality because it has a profound immunosuppressive effect, but the available evidence of its use for AR is insufficient. Therefore, rigorously designed randomized controlled trials (RCTs) are needed. Our objective is to describe the protocol for a feasibility trial to assess the effects and safety of intranasal phototherapy for the treatment of AR.
Methods And Analysis: This is a study protocol for a single-center, randomized, double-blind, parallel, placebo-controlled, investigator-initiated pilot study. A total of 40 patients with AR will be randomly assigned to the medical device or sham device group in a 1:1 ratio. The participants will receive intranasal phototherapy with a medical or sham device for 20 min 5 times a week for 2 weeks. The primary outcome will be the mean change in the Total Nasal Symptom Score (TNSS) from baseline to 2 weeks. The secondary outcomes will include the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, Nasal Endoscopy Index, total serum Ig E level, and eosinophil count.
Discussion: The findings of this study will provide the basis for subsequent large-scale definitive RCTs to confirm the effects and safety of intranasal phototherapy for the treatment of nasal symptoms in patients with AR who do not respond well to conventional therapy. This study may assist in the development of noninvasive treatment for patients with AR.
Trial Registration: This study was registered at the Korean National Clinical Trial Registry, Clinical Research Information Service (KCT0003253).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387024 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000020835 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bio-intelligent plasma-engineered diferuloylmethane/fucoidan/neutrophil lysate/iron oxide nanoclusters for phototherapeutic and magnetotherapeutic with in situ magnetic gelation mitigating inflammatory diseases.
Colloids Surf B Biointerfaces
November 2024
Graduate Institute of Biomedical Materials and Tissue Engineering, International Ph.D. Program in Biomedical Engineering, Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan, Republic of China; Department of Orthopedics, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan, Republic of China; Department of Orthopedics, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, Republic of China; Research Center of Biomedical Devices, Taipei Medical University, Taipei 11031, Taiwan, Republic of China; International Ph.D. Program for Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, Republic of China. Electronic address:
Creating a versatile and remotely self-assembling biocomposite for delivering therapeutics to alleviate inflammatory diseases poses significant challenges. This study introduces a novel biocomposite, created through cold-atmosphere plasma treatment, that combines fucoidan (Fu) and neutrophil lysate (Nu) to mediate the self-assembly of diferuloylmethane (DIF) and iron oxide (IO) nanoclusters, termed DIF-Nu/Fu-IO NC. This biocomposite forms a phototherapeutic and magnetically-driven in situ gel with open-porous architecture loaded with DIF, offering non-invasive theranostic capabilities for treating inflammatory diseases.
View Article and Find Full Text PDFPhotobiomodulation Treatment with a Home-Use Device for COVID-19: A Randomized Controlled Trial for Efficacy and Safety.
Photobiomodul Photomed Laser Surg
June 2024
University of Johannesburg, Doornfontein, South Africa.
Photobiomodulation therapy (PBMT) using devices to deliver red and/or near-infrared light to tissues has shown promising effects in clinical settings for respiratory diseases, including potential benefits in managing symptoms associated with COVID-19. To determine if at-home self-administered PBMT for patients with COVID-19 is safe and effective. This was a randomized controlled trial (RCT) carried out at home during the COVID-19 pandemic (September 2020 to August 2021).
View Article and Find Full Text PDFPhotobiomodulation Therapy on Brain: Pioneering an Innovative Approach to Revolutionize Cognitive Dynamics.
Cells
June 2024
Department of Biomedical Engineering, Keimyung University, Daegu 42601, Republic of Korea.
Photobiomodulation (PBM) therapy on the brain employs red to near-infrared (NIR) light to treat various neurological and psychological disorders. The mechanism involves the activation of cytochrome c oxidase in the mitochondrial respiratory chain, thereby enhancing ATP synthesis. Additionally, light absorption by ion channels triggers the release of calcium ions, instigating the activation of transcription factors and subsequent gene expression.
View Article and Find Full Text PDFThe Effect of Intranasal Plus Transcranial Photobiomodulation on Neuromuscular Control in Individuals with Repetitive Head Acceleration Events.
Photobiomodul Photomed Laser Surg
June 2024
Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
This proof-of-concept study was to investigate the relationship between photobiomodulation (PBM) and neuromuscular control. The effects of concussion and repetitive head acceleration events (RHAEs) are associated with decreased motor control and balance. Simultaneous intranasal and transcranial PBM (itPBM) is emerging as a possible treatment for cognitive and psychological sequelae of brain injury with evidence of remote effects on other body systems.
View Article and Find Full Text PDFBrain photobiomodulation therapy on neurological and psychological diseases.
J Biophotonics
January 2024
School of Materials Science and Engineering, Hefei University of Technology, Hefei, China.
Photobiomodulation (PBM) therapy is an innovative treatment for neurological and psychological conditions. Complex IV of the mitochondrial respiratory chain can be stimulated by red light, which increases ATP synthesis. In addition, the ion channels' light absorption causes the release of Ca which activates transcription factors and changes gene expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!